SC 13D/A

 

 

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

SCHEDULE 13D/A

Under the Securities Exchange Act of 1934

(Amendment No. 3)*

 

 

Crinetics Pharmaceuticals, Inc.

(Name of Issuer)

Common Stock, $0.001 par value

(Title of Class of Securities)

22663K 107

(CUSIP Number)

Alexander Rakitin

Perceptive Advisors LLC

51 Astor Place, 10th Floor

New York, NY 10003

(646) 205-5340

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

April 18, 2022

(Date of Event Which Requires Filing of this Statement)

 

 

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ☐

 

 

Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Section 240.13d-7 for other parties to whom copies are to be sent.

 

 

*

The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 

 


CUSIP No. 22663K 107

 

 

  1.    

  Names of Reporting Persons.

 

  Perceptive Advisors LLC

  2.  

  Check the Appropriate Box if a Member of a Group (See Instructions)

  (a)  ☐        (b)  ☒

 

  3.  

  SEC Use Only

 

  4.  

  Source of Funds (See Instructions)

 

  AF

  5.  

  Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)

 

  ☐

  6.  

  Citizenship or Place of Organization

 

  Delaware

Number of

Shares

 Beneficially 

Owned by

Each

Reporting

Person

With

 

     7.     

  Sole Voting Power

 

  0

     8.   

  Shared Voting Power

 

  5,333,532

     9.   

  Sole Dispositive Power

 

  0

   10.   

  Shared Dispositive Power

 

  5,333,532

11.    

  Aggregate Amount Beneficially Owned by Each Reporting Person

 

  5,333,532

12.  

  Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

 

  ☐

13.  

  Percent of Class Represented by Amount in Row (11)

 

  10.0%

14.  

  Type of Reporting Person (See Instructions)

 

  IA

 

 


CUSIP No. 22663K 107

 

 

  1.    

  Names of Reporting Persons.

 

  Joseph Edelman

  2.  

  Check the Appropriate Box if a Member of a Group (See Instructions)

  (a)  ☐        (b)  ☒

 

  3.  

  SEC Use Only

 

  4.  

  Source of Funds (See Instructions)

 

  AF

  5.  

  Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)

 

  ☐

  6.  

  Citizenship or Place of Organization

 

  United States of America

Number of

Shares

 Beneficially 

Owned by

Each

Reporting

Person

With

 

     7.     

  Sole Voting Power

 

  0

     8.   

  Shared Voting Power

 

  5,333,532

     9.   

  Sole Dispositive Power

 

  0

   10.   

  Shared Dispositive Power

 

  5,333,532

11.    

  Aggregate Amount Beneficially Owned by Each Reporting Person

 

  5,333,532

12.  

  Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

 

  ☐

13.  

  Percent of Class Represented by Amount in Row (11)

 

  10.0%

14.  

  Type of Reporting Person (See Instructions)

 

  IN

 


CUSIP No. 22663K 107

 

 

  1.    

  Names of Reporting Persons.

 

  Perceptive Life Sciences Master Fund, Ltd.

  2.  

  Check the Appropriate Box if a Member of a Group (See Instructions)

  (a)  ☐        (b)  ☒

 

  3.  

  SEC Use Only

 

  4.  

  Source of Funds (See Instructions)

 

  WC

  5.  

  Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)

 

  ☐

  6.  

  Citizenship or Place of Organization

 

  Cayman Islands

Number of

Shares

 Beneficially 

Owned by

Each

Reporting

Person

With

 

     7.     

  Sole Voting Power

 

  0

     8.   

  Shared Voting Power

 

  5,333,532

     9.   

  Sole Dispositive Power

 

  0

   10.   

  Shared Dispositive Power

 

  5,333,532

11.    

  Aggregate Amount Beneficially Owned by Each Reporting Person

 

  5,333,532

12.  

  Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

 

  ☐

13.  

  Percent of Class Represented by Amount in Row (11)

 

  10.0%

14.  

  Type of Reporting Person (See Instructions)

 

  CO

 


Item 2. Identity and Background

Item 2 of the Schedule 13D is amended and supplemented as follows:

Schedule A attached hereto sets forth the information regarding the directors of the Master Fund.

Item 5. Interest in Securities of the Issuer

Item 5 is amended and restated as follows:

 

  (a)

The information set forth in rows 11 and 13 of the cover pages to this Schedule 13D is incorporated by reference. The percentage set forth in row 13 is based on 53,223,790 outstanding shares of Common Stock, as reported by the Company in its prospectus filed with the Securities and Exchange Commission on April 13, 2022.

 

  (b)

The information set forth in rows 7 through 10 of the cover pages to this Schedule 13D is incorporated by reference. The beneficial owneership reported on this Schedule 13D reflects 5,321,032 shares of Common Stock held by the Master Fund and warrants exercisable for 12,500 shares of Common Stock held by the Master Fund.

 

  (c)

Schedule B sets forth all transactions with respect to the shares of Common Stock effected during the past sixty days by any Reporting Person.

 

  (d)

No person (other than the Reporting Persons) is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the shares of Common Stock subject to this Schedule 13D.

 

  (e)

Not applicable.


SIGNATURES

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: April 20, 2022

PERCEPTIVE ADVISORS LLC

 

By:  

/s/ Joseph Edelman

  Name: Joseph Edelman
  Title:   Managing Member

 

/s/ Joseph Edelman

JOSEPH EDELMAN

PERCEPTIVE LIFE SCIENCES MASTER FUND, LTD.

 

By:

Perceptive Advisors LLC

 

By:  

/s/ Joseph Edelman

  Name: Joseph Edelman
  Title:   Managing Member


Schedule A

The following sets forth the name, address, principal occupation, citizenship and beneficial ownership of the shares of Common Stock (to the extent not pursuant to Item 5(a)) of each director of the Master Fund.

 

Master Fund

Name and Citizenship

  

Position

  

Principal Business Address

  

Beneficial Ownership of

Shares of Common Stock

Scott Dakers

(United Kingdom)

   Director   

c/o Elian Fiduciary Services (Cayman) Limited

190 Elgin Avenue, George Town

Grand Cayman KY1-9007

Cayman Islands

   None

Ernest A. Morrison

(United Kingdom)

   Director   

Cox Hallett Wilkinson

Milner House

18 Parliament Street

P.O. Box HM 1561

Hamilton HM FX

Bermuda

   None

James Nicholas

(United States

   Director   

c/o GenesisPoint LLC

30 Old Kings Highway S

Darien, CT 06820

   None


Schedule B

 

Name

   Date of Transaction      Amount of Securities      Price per Share  

Master Fund

     April 18, 2022        157,515      $ 22.22